Processa Pharmaceuticals presents at Orphan Drugs Congress; no material new data disclosed

Processa Pharmaceuticals, Inc.

Dr. David Young, President of R&D, presented on Nov 16, 2023 at 2:40 PM ET at the 20th Orphan Drugs and Rare Diseases Global Congress in Boston.
Presentation title: 'Benefit-Risk Analysis for FDA Approval Requires More Than a Pivotal Trial'.
Presentation furnished as Exhibit 99.1 but exhibit text not provided; no specific numbers, milestones, or guidance detailed in the 8-K.
Company undertakes no obligation to update this Reg FD disclosure; no changes to business or financial condition reported.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.